AU2018269745C1 - Compounds, compositions and methods - Google Patents

Compounds, compositions and methods Download PDF

Info

Publication number
AU2018269745C1
AU2018269745C1 AU2018269745A AU2018269745A AU2018269745C1 AU 2018269745 C1 AU2018269745 C1 AU 2018269745C1 AU 2018269745 A AU2018269745 A AU 2018269745A AU 2018269745 A AU2018269745 A AU 2018269745A AU 2018269745 C1 AU2018269745 C1 AU 2018269745C1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
alkyl
heterocyclyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018269745A
Other languages
English (en)
Other versions
AU2018269745A1 (en
AU2018269745B2 (en
Inventor
Giorgio Bonanomi
Javier De Vicente Fidalgo
Anthony A. ESTRADA
Jianwen A. FENG
Brian Fox
Cinzia Maria FRANCINI
Cheng Hu
Colin Philip Leslie
Maksim OSIPOV
Anantha Sudhakar
Zachary K. Sweeney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of AU2018269745A1 publication Critical patent/AU2018269745A1/en
Publication of AU2018269745B2 publication Critical patent/AU2018269745B2/en
Priority to AU2022202524A priority Critical patent/AU2022202524B2/en
Application granted granted Critical
Publication of AU2018269745C1 publication Critical patent/AU2018269745C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018269745A 2017-05-17 2018-05-17 Compounds, compositions and methods Ceased AU2018269745C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202524A AU2022202524B2 (en) 2017-05-17 2022-04-14 Compounds, compositions and methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507682P 2017-05-17 2017-05-17
US62/507,682 2017-05-17
PCT/US2018/033269 WO2018213634A1 (en) 2017-05-17 2018-05-17 Compounds, compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202524A Division AU2022202524B2 (en) 2017-05-17 2022-04-14 Compounds, compositions and methods

Publications (3)

Publication Number Publication Date
AU2018269745A1 AU2018269745A1 (en) 2019-11-28
AU2018269745B2 AU2018269745B2 (en) 2022-01-27
AU2018269745C1 true AU2018269745C1 (en) 2022-06-09

Family

ID=64274734

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018269745A Ceased AU2018269745C1 (en) 2017-05-17 2018-05-17 Compounds, compositions and methods
AU2022202524A Ceased AU2022202524B2 (en) 2017-05-17 2022-04-14 Compounds, compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202524A Ceased AU2022202524B2 (en) 2017-05-17 2022-04-14 Compounds, compositions and methods

Country Status (11)

Country Link
US (2) US11174262B2 (https=)
EP (1) EP3625234B1 (https=)
JP (2) JP7140781B2 (https=)
KR (1) KR102637541B1 (https=)
CN (1) CN110914275A (https=)
AU (2) AU2018269745C1 (https=)
BR (1) BR112019023979A2 (https=)
CA (1) CA3063938A1 (https=)
IL (1) IL270505B2 (https=)
MX (1) MX2019013642A (https=)
WO (1) WO2018213634A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7208137B2 (ja) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
JP7140781B2 (ja) * 2017-05-17 2022-09-21 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
EP4422621A4 (en) * 2021-10-27 2025-08-27 Merck Sharp & Dohme Llc SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF
WO2025045281A2 (zh) * 2023-08-31 2025-03-06 杭州百诚医药科技股份有限公司 苯并氮杂䓬酮类化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290952A (en) * 1980-06-23 1981-09-22 American Home Products Corporation Aryl-1-mercaptoalkanoylproline and homoproline derivatives
US20100190688A1 (en) * 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
US20110305777A1 (en) * 2006-07-24 2011-12-15 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2016094846A1 (en) * 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
BRPI0506883A (pt) 2004-01-16 2007-05-29 Univ Michigan miméticos de smac conformacionalmente comprimidos e seus usos
US7989441B2 (en) 2005-06-08 2011-08-02 Novartis Ag Organic compounds
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
CN108440571B (zh) 2012-10-22 2022-11-04 希望之城 Etp衍生物
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3224245B1 (en) * 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
JP7140781B2 (ja) * 2017-05-17 2022-09-21 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290952A (en) * 1980-06-23 1981-09-22 American Home Products Corporation Aryl-1-mercaptoalkanoylproline and homoproline derivatives
US20100190688A1 (en) * 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
US20110305777A1 (en) * 2006-07-24 2011-12-15 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2016094846A1 (en) * 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Also Published As

Publication number Publication date
AU2018269745A1 (en) 2019-11-28
IL270505A (https=) 2019-12-31
EP3625234A4 (en) 2021-03-10
IL270505B1 (en) 2023-05-01
US11174262B2 (en) 2021-11-16
US11851433B2 (en) 2023-12-26
WO2018213634A1 (en) 2018-11-22
US20220024938A1 (en) 2022-01-27
IL270505B2 (en) 2023-09-01
JP7140781B2 (ja) 2022-09-21
AU2022202524A1 (en) 2022-05-12
BR112019023979A2 (pt) 2020-06-09
CN110914275A (zh) 2020-03-24
MX2019013642A (es) 2020-07-20
EP3625234B1 (en) 2023-09-20
US20200079784A1 (en) 2020-03-12
AU2018269745B2 (en) 2022-01-27
KR102637541B1 (ko) 2024-02-15
CA3063938A1 (en) 2018-11-22
AU2022202524B2 (en) 2023-10-05
KR20200006120A (ko) 2020-01-17
JP2022174180A (ja) 2022-11-22
JP2020520925A (ja) 2020-07-16
EP3625234A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
AU2022202524B2 (en) Compounds, compositions and methods
US10709692B2 (en) Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
AU2018313850B2 (en) Compounds, compositions and methods
TWI786049B (zh) 化合物、組合物及方法
JP5699146B2 (ja) 縮合アミノジヒドロピリミドン誘導体
US12180211B2 (en) Compounds, compositions and methods
KR20200101402A (ko) Tlr 억제제로서 유용한 치환된 인돌 화합물
WO2018213632A1 (en) Kinase inhibitors and uses thereof
KR20150119926A (ko) 비시클로 2,3-벤조디아제핀 및 스피로시클릭 치환된 2,3-벤조디아제핀
JP6276852B2 (ja) 新規化合物、使用およびそれらの調製のための方法
HK40016450B (en) Compounds useful as ripk1 inhibitors
EA052777B1 (ru) Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAR 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 02 MAR 2022

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired